The Cancer Prevention and Control Program (CPC) organizes and promotes all cancer prevention and control-related research activities in the Winship Cancer Institute (Winship) and across Emory University. The CPC Program capitalizes on being in a research university with schools of medicine and nursing and a full-featured, nationally ranked school of public health from which to build a cancer center program that addresses the full spectrum of cancer prevention and control research. Research within the program is characterized by four scientific themes: 1) Cancer Epidemiology, Biomarkers, and Chemoprevention;2) Health Behavior Research;3) Symptom Management and Control;and 4) Health Outcomes and Quality of Care. These themes address the program's goals of reducing cancer risk, incidence, morbidity, and mortality in Georgia through: describing and tracking cancer incidence and mortality trends of all cancers;conducting population-based etiologic research in humans;conducting chemoprevention trials in Georgia and in national collaborations;conducting research that applies theories of human behavior to prevent cancer through early detection;conducting research to characterize the scope of behavioral co-morbidities which occur in patients with cancer;understanding relevant mechanisms and treatments of these behavioral co-morbidities;and conducting research that describes, interprets, and predicts the impact of interventions and other factors on cancer outcomes important to decision makers. The CPC Program has members from 12 departments across all three schools within Emory University: the Schools of Public Health, Nursing, and Medicine. The program has 31 core members and 12 coalition members (persons in non-affiliated institutions in Atlanta [i.e., the American Cancer Society and the Center for Disease Control and Prevention] who actively participate in the CPC Program's activities), and a portfolio of 42 NIH and other national, peer-reviewed, cancer-related grants headed by 20 core members, with a combined annual funding of $9,763,879 in program direct costs (out of a total of 57 externally-funded cancer research grants with $11,188,786 in program direct costs). The number of peer-reviewed cancer publications by CPC core members during the current grant period was 247, of which 24% were Intraprogrammatic and 14% were inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-05
Application #
8520238
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$27,974
Indirect Cost
$10,032
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Hou, Yue; Konen, Jessica; Brat, Daniel J et al. (2018) TASI: A software tool for spatial-temporal quantification of tumor spheroid dynamics. Sci Rep 8:7248
Greenwell, I Brian; Staton, Ashley D; Lee, Michael J et al. (2018) Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer 124:2306-2315
Patel, Mihir R; Hudgins, Patricia A; Beitler, Jonathan J et al. (2018) Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. ORL J Otorhinolaryngol Relat Spec 80:85-95
Sadigh, Gelareh; Duszak Jr, Richard; Ward, Kevin C et al. (2018) Downstream Breast Imaging Following Screening Mammography in Medicare Patients with Advanced Cancer: A Population-Based Study. J Gen Intern Med 33:284-290
Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166
Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432
Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7
Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895
Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298
Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153

Showing the most recent 10 out of 331 publications